Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 in de Novo and Maintenance Kidney Transplant Recipients
NCT03663335Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of iscalimab in kidney transplantation, sponsored by Novartis. Started Nov 2018; status: completed.
02
Drugs
iscalimab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT03663335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663335.